UV Flu Technologies Inc. Announces Growth of National Distributor Network for UV-400 Bacteria Killing Air Purifier

CENTERVILLE, MA--(Marketwire - November 02, 2010) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is pleased to announce the recent signing of agreements with 3 new distributors to commence offering the ViraTech UV-400 to their market segment commercial accounts.

The new distributors include Emerald Medical Service, a supplier of medical equipment throughout the Washington, DC area, UV Air, a supplier to government, schools, and hotels in the Woburn, MA area, and Factory-Direct Green, a distributor servicing over 400 hotel customers in the Carlsbad, California area.

“These agreements represent the beginning of our national initiative to add key representatives and distributors to cover our 5 primary target markets and segments. We identify those markets in no particular order as: Hospitality, including hotels, casinos, and spas; Medical, including hospitals, medical offices and nursing homes; the Government sector, which includes a huge inventory of installations, schools, Indian reservations and government offices; Athletics, including health clubs and sports teams; and Volatile Organic Compound (VOC) locations, which include many salons, laboratories and funeral homes,” said Jack Lennon, President of UV Flu.

Mr. Lennon continues, “These new distributors have existing relationships in their respective segments, and are all actively diversifying their reach. As an example, we have been advised that just this week UV Air added Tactical Office Solutions in Woburn, MA to their client list. Tactical is an organization owned and operated by a disabled service veteran, and works exclusively within the government sector. With this in mind, UV Flu has begun all appropriate steps towards full eligibility under government procurement processes. With the addition of our new distributors, the Company is confident it will be announcing national accounts, including government contracts in the near future.”

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information, visit: www.uvflutech.com.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC’s (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
-----------------------------
John J. Lennon, President & CEO


Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Web: www.uvflutech.com

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: UV-400 Indoor air quality clean air NDM-1 H1N1 MRSA FLU Virus Bacteria Lennon Pure Air

MORE ON THIS TOPIC